The present application relates to novel combinations of at least two components, component A and component B: ● component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof； ● component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof； and, optionally, ● one or more components C which are pharmaceutical products: in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.本申請案係關於用於治療及/或預防疾病之至少兩種組分，組分A及組分B之新穎組合：●組分A為如本文所定義之IRAK4抑制性式(I)化合物，或其非對映異構體、對映異構體、代謝物、鹽、溶劑合物或鹽之溶劑合物；●組分B為BTK抑制性化合物，或其醫藥學上可接受之鹽；及，視情況選用之●一或多種組分C，其為醫藥產品；其中上文所定義之化合物A及B中之一者或兩者視情況存在於準備用於同時、單獨或依序投藥之醫藥調配物中，且係關於其於製備用以治療及/或預防疾病，尤其用以治療及/或預防子宮內膜異位、淋巴瘤、黃斑變性、COPD、贅生性病症及牛皮癬之藥劑上的用途。
